Clinical Trial ProgressBlinded interim analysis trial has revealed a positive trend on forced vital capacity (FVC), and an independent monitoring committee has opined that the trial should continue as is.
Drug EfficacySTAT3 inhibition can curb a range of inflammatory and fibrotic pathways, potentially driving a superior FVC response versus standard of care.
Market OpportunityConsidering the favorable risk-reward on TVRD shares ahead of 2H25 data, a buying opportunity is observed.